Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells.
Metabolites • Vol. 12, Issue 10 • 2022
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.
Expert opinion on investigational drugs • Vol. 29, Issue 2 • 2020
Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
PloS one • Vol. 15, Issue 1 • 2020
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Expert opinion on investigational drugs • Vol. 29, Issue 2 • 2020
